РОЛЬ ДЕМОГРАФИЧЕСКИХ И СОЦИАЛЬНЫХ ФАКТОРОВ В ДИАГНОСТИКЕ И ПРОФИЛАКТИКЕ COVID-19: ИССЛЕДОВАНИЕ В ГОРОДЕ СЕМЕЙ
2025 жыл | Шығарылым: 2 | Беттер: 124-133
ANALYSIS OF ANTIBIOTIC PRESCRIBING PRACTICES IN PRIMARY HEALTH CARE SETTINGS. PART I
2025 жыл | Шығарылым: 2 | Беттер: 134-144
GENETIC SUSCEPTIBILITY TO RADIATION-RELATED DISEASES: A REVIEW OF CURRENT LITERATURE
2025 жыл | Шығарылым: 2 | Беттер: 145-153
ТЕНДЕНЦИИ ЗАБОЛЕВАЕМОСТИ ИНФЕКЦИОННОГО ЭНДОКАРДИТА ПОСЛЕ ОБНОВЛЕНИЯ МЕЖДУНАРОДНЫХ РУКОВОДСТВУЮЩИХ ПРИНЦИПОВ. ОБЗОР ЛИТЕРАТУРЫ
2025 жыл | Шығарылым: 2 | Беттер: 154-167
СРАВНЕНИЕ МЕТОДОВ МОДЕЛИРОВАНИЯ РЕЦЕССИИ ДЕСНЫ НА ЛАБОРАТОРНЫХ ЖИВОТНЫХ
2025 жыл | Шығарылым: 2 | Беттер: 168-178
CHEMOTHERAPY-INDUCED ECHOCARDIOGRAPHY CHANGES IN HEPATOCELLULAR CARCINOMA PATIENTS
2025 жыл | Шығарылым: 6 | Беттер: 47-53
EVALUATION OF THE SATISFACTION AND SUCCESS LEVELS OF BASIC LIFE SUPPORT, ADVANCED CARDIAC LIFE SUPPORT, AND TRAUMA TRAININGS PROVIDED TO SIXTH-YEAR STUDENTS OF MEDICAL FACULTY KARADENIZ TECHNICAL UNIVERSITY
2025 жыл | Шығарылым: 6 | Беттер: 54-66
THE EFFECT OF PRECONCEPTION CARE ON PERINATAL OUTCOMES OF THE MOTHER-PLACENTA-FETUS SYSTEM
2025 жыл | Шығарылым: 6 | Беттер: 67-76
MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND ABLATION IN THE MANAGEMENT OF SYMPTOMATIC ADENOMYOSIS: ASSESSMENT OF CLINICAL EFFICACY, SAFETY, AND IMPACT ON FERTILITY. A CASE SERIES
2025 жыл | Шығарылым: 6 | Беттер: 77-83
VALIDATION OF THE RUSSIAN AND KAZAKH VERSIONS OF THE PSQ-18: ADAPTED INSTRUMENT FOR PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS
2025 жыл | Шығарылым: 6 | Беттер: 84-90
USING OF ATORIS AT FEMALES WITH ARTERIAL HYPERTENSION AND HYPERLIPIDEMIA
So, medicine Atoris is may be used as high effective lipid lowering drug for secondary prophylaxis of cardiovascular compli-cations at females with high risk of ischemic heart disease.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 40-42
ARTERIAL HYPERTENSION AT OLD AGE PATIENTS
Problem of arterial hypertension at old age patients is connected with it’s wide spreading and tendency to aging of popu-lation. In old age there are different risk factors and accompanying diseases, which permit to say about that group of patients are in high or very high risk of cardiovascular complications not depending on degree of increasing of blood pressure.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 38-40
DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (CHF)
This lecture consist of actuality, definition, main etiological factors of chronic heart failure and diagnostic criteria. And there is medicamentous therapy and principles of surgical and electrophysiological methods of treatment of CHF in this lecture.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 32-37
CALCIUM CHANNELS BLOCKERS - A ROLE IN MODERN THERAPY OF CARDIOVASCULAR DISEASES: IN FOCUS – DILTIAZEM
Calcium channels blockers – group of the drugs which basic property is ability to brake a calcium current inside of smooth muscle cells through the special channels named “slow calcium channels”. Diltiazem Lannacher renders cardioprotective action with antioxidative effect, angioprotective action, antiagregant action, antiatherogenous action, nephroprotective action, cerebroprotective action.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 24-34
DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AT TREATMENT OF ARTERIAL HYPERTENSION: LERKAMEN
Arterial hypertension (AH) is independent risk factor of myocardial infarction, brain stroke, chronic heart failure (CHF) and hypertensive nephropathy, death from cardiovascular diseases.
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 18-24